OKYO
OKYO Pharma Limited Ordinary Shares
Latest price
As of Oct 27, 2026, 4:00 PM EDT · Market data by Massive
Market cap
$75.6M
Volume
11.3K
Previous close
$1.44
Day range
$1.41 – $1.51
Listed
May 17, 2022
Coverage
9 articles
Price performance
Recent trading
Newsroom
Latest OKYO coverage
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that its first drug candidate OK-101, present
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that the first patient has been screened for its phase 2, multi-center, randomized, double–blinded, placebo-con
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded,
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, announced the pricing of a reasonable best efforts public offering of 3,503,665 American Depositary Shares (the “ADSs”) at a public
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
[ad_1] CEO of OKYO Pharma, Inc., Dr. Gary Jacob, Interviewed by Leading Publisher, SmallCapsDaily New York, NY – (NewMediaWire) – March 10, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet nee
OKYO Pharma: An Emerging Biopharma With Game Changing Treatments In Ophthalmology
OKYO Pharma's main drug has already surpassed Phase 1 and reached Phase 2. OK-101 is catering to niches within the domain of ophthalmic diseases and is expected to see its core drug candidate in Phase 2 of clinical trials in the very near future.
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the appointment of Jay S. Pepose, M.D., Ph.D., Founder and Medical Director of the Pepose Vision Institute and Professor
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation entitled: “A Lipidated Protease-Resistant Che